Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
149 hedge funds and large institutions have $327M invested in Achillion Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 55 increasing their positions, 32 reducing their positions, and 12 closing their positions.
200% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 12
72% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 32
59% more call options, than puts
Call options by funds: $983K | Put options by funds: $617K
19% more funds holding
Funds holding: 125 → 149 (+24)
32% less capital invested
Capital invested by funds: $480M → $327M (-$153M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$20.7M |
| 2 |
Morgan Stanley
New York
|
+$15.6M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.69M |
| 4 |
BlackRock
New York
|
+$6.31M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$47.4M |
| 2 |
O
OrbiMed
New York
|
-$17.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$10.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.61M |
| 5 |
AC
Armistice Capital
New York
|
-$4.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
151
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.35M | -300,000 | Closed |
|
|
PP
152
PDT Partners
New York
| – | -$970K | -216,000 | Closed |
|
|
NFA
153
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$409K | -90,991 | Closed |
|
|
BCM
154
Bayesian Capital Management
Brooklyn,
New York
| – | -$203K | -45,106 | Closed |
|
155
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$113K | -25,228 | Closed |
|
156
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$98K | -21,880 | Closed |
|
|
SBIA
157
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
| – | -$55K | -12,300 | Closed |
|
|
TRCT
158
Tower Research Capital (TRC)
New York
| – | -$38.7K | -10,659 | Closed |
|
|
MWM
159
MinichMacGregor Wealth Management
Saratoga Springs,
New York
| – | -$7K | -1,740 | Closed |
|
|
NFG
160
Next Financial Group
Houston,
Texas
| – | -$3K | -600 | Closed |
|
|
IA
161
IFP Advisors
Tampa,
Florida
| – | -$1.93K | -530 | -84% |
|
ACHN Hedge Fund Activity: Q4 2017 in Review
149 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2017, worth a combined $327M — down 32% from $480M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ACHN positions and 12 closed out — a net gain of 24 holders — while 55 added to existing stakes and 32 trimmed.
The largest buyer was RTW Investments, adding an estimated $20.7M. The largest seller was RA Capital Management, cutting an estimated $47.4M.
- 149 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2017, up from 125 in Q3 2017.
- Funds reported $327M of Achillion Pharmaceuticals stock for Q4 2017, down 32% quarter-over-quarter.
- 36 funds opened new Achillion Pharmaceuticals positions in Q4 2017 and 12 closed out, a net change of +24 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2017 was RTW Investments, an estimated $20.7M added.
- The largest Achillion Pharmaceuticals seller in Q4 2017 was RA Capital Management, an estimated $47.4M sold.
Based on aggregated 13F filings for Q4 2017.